Loading candles…
Biocon Ltd. is an India-based global biopharmaceutical company operating in the biotechnology and biopharmaceutical industries. The company focuses on developing and manufacturing affordable therapies for chronic diseases such as diabetes, oncology, and immunology. It operates through four main business segments: Generics, Biosimilars via its subsidiary Biocon Biologics, Research Services through its subsidiary Syngene, and Novel Biologics. Biocon employs a vertically integrated model managing the entire value chain from discovery to commercialization. Its products and services include biotechnology product manufacturing and research services. The company serves customers in over 120 countries worldwide.
| Type | Details | Date |
|---|---|---|
| Fund Raising | To consider Fund Raising | 7 May 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and dividend | 7 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 12 Feb 2026 |
| Fund Raising | To consider Fund Raising | 6 Dec 2025 |
| Intimation | Update on prior intimation of Board Meeting to be held for consideration and approval of early redemption of NCDs and raising of funds through issuance of Co… | 11 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 11 Nov 2025 |
| Other | To consider other business matters inter alia, Early Redemption of NCDs | 1 Oct 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 7 Aug 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.